Marex Group plc Buys New Shares in Edwards Lifesciences Corporation $EW

Marex Group plc purchased a new position in Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 6,061 shares of the medical research company’s stock, valued at approximately $474,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Quantbot Technologies LP bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $26,000. Rosenberg Matthew Hamilton bought a new stake in Edwards Lifesciences in the second quarter valued at approximately $28,000. NewSquare Capital LLC boosted its stake in shares of Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 134 shares during the period. Rakuten Securities Inc. grew its holdings in shares of Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after purchasing an additional 302 shares during the last quarter. Finally, Riverview Trust Co increased its stake in shares of Edwards Lifesciences by 44.5% in the second quarter. Riverview Trust Co now owns 516 shares of the medical research company’s stock worth $40,000 after buying an additional 159 shares during the period. 79.46% of the stock is owned by institutional investors.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $84.03, for a total transaction of $85,626.57. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,848,828.06. This trade represents a 4.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,370,184.06. This represents a 16.18% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 45,465 shares of company stock valued at $3,804,610. 0.34% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

EW stock opened at $83.41 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The firm has a 50 day moving average price of $81.75 and a 200-day moving average price of $79.09. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The firm has a market capitalization of $48.40 billion, a price-to-earnings ratio of 35.95, a PEG ratio of 3.73 and a beta of 0.97.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the previous year, the business earned $0.67 earnings per share. The firm’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on EW shares. Jefferies Financial Group set a $98.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Wednesday, October 29th. Wall Street Zen cut Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Piper Sandler reaffirmed an “overweight” rating and set a $95.00 price target (up previously from $90.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. UBS Group set a $92.00 price objective on Edwards Lifesciences in a research report on Friday, December 5th. Finally, Truist Financial set a $92.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, December 5th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $93.45.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.